Tolevamer, an orally administered, toxin-binding polymer for Clostridium difficile-associated diarrhea.
Genzyme Corp is developing tolevamer, an anionic toxin-binding polymer that binds and neutralizes the Clostridium difficile A and B toxins, for the potential treatment of C difficile-associated diarrhea (CDAD). Two phase III clinical trials of tolevamer in patients with CDAD have been completed and results from the second trial are expected to be released imminently.
Scheinfeld, N; Biggers, K
Volume / Issue
Start / End Page
International Standard Serial Number (ISSN)